MetaCap

Nurix Therapeutics (NRIX) vs Rapport Therapeutics (RAPP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rapport Therapeutics (RAPP) has outperformed Nurix Therapeutics (NRIX) over the past year, losing 15.0% versus a loss of 23.3%. Nurix Therapeutics is the larger company by market cap ($1.40 billion vs $1.37 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NRIX-23.33%RAPP-15.01%
+98%+35%-29%
Nov 21, 20251 yearNov 20, 2026
NRIX-18.05%RAPP+11.35%
+144%+37%-70%
Jun 3, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NRIX versus RAPP key metrics
MetricNRIXRAPP
Share price$12.85$23.16
Market cap$1.40B$1.37B
1-day change-5.55%-1.82%
YTD return-32.26%-23.67%
1-year return-23.33%-15.01%
5-year return-57.25%—
P/E ratio (TTM)5.29—
EPS (TTM)$2.43$-3.17
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$83.98M—
Revenue growth (YoY)+53.95%—
Net income (latest FY)$-264.46M$-111.48M
Operating margin-340.16%—
Net margin-314.90%—
52-week high$28.23$52.93
52-week low$12.83$22.06
Distance from 52-week high-54.50%-56.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+160.80%+177.25%
Average volume2.47M790.62K
Shares outstanding109.25M59.28M
Employees31784
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Nurix Therapeutics

NRIX stock →

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees

About Rapport Therapeutics

RAPP stock →

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

NRIX vs RAPP FAQ

Which is bigger, Nurix Therapeutics or Rapport Therapeutics?

Nurix Therapeutics (NRIX) is larger, with a market capitalization of $1.40B compared with $1.37B for Rapport Therapeutics (RAPP).

Which stock has performed better over the past year, NRIX or RAPP?

RAPP returned -15.01% over the past 12 months, compared with -23.33% for NRIX (price return, excluding dividends). Past performance does not predict future results.

Are Nurix Therapeutics and Rapport Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons